Next Article in Journal
1984—Discovery of the First Anti-HIV Drug, Suramin
Previous Article in Journal
Barriers towards HPV Vaccinations for Boys and Young Men: A Narrative Review
Article

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates

1
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
2
Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
3
CureVac AG, 72076 Tuebingen, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Andrew Davidson
Viruses 2021, 13(8), 1645; https://doi.org/10.3390/v13081645
Received: 7 July 2021 / Revised: 13 August 2021 / Accepted: 17 August 2021 / Published: 19 August 2021
(This article belongs to the Section Coronaviruses)
Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates. View Full-Text
Keywords: SARS-CoV-2; CureVac; COVID; vaccine; NHP SARS-CoV-2; CureVac; COVID; vaccine; NHP
Show Figures

Figure 1

MDPI and ACS Style

van Doremalen, N.; Fischer, R.J.; Schulz, J.E.; Holbrook, M.G.; Smith, B.J.; Lovaglio, J.; Petsch, B.; Munster, V.J. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses 2021, 13, 1645. https://doi.org/10.3390/v13081645

AMA Style

van Doremalen N, Fischer RJ, Schulz JE, Holbrook MG, Smith BJ, Lovaglio J, Petsch B, Munster VJ. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses. 2021; 13(8):1645. https://doi.org/10.3390/v13081645

Chicago/Turabian Style

van Doremalen, Neeltje, Robert J. Fischer, Jonathan E. Schulz, Myndi G. Holbrook, Brian J. Smith, Jamie Lovaglio, Benjamin Petsch, and Vincent J. Munster 2021. "Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates" Viruses 13, no. 8: 1645. https://doi.org/10.3390/v13081645

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop